.

The pace of innovation, both technically and in terms of commercialization strategies, continues to accelerate within the field of molecular diagnostics, making the right strategic partnerships critical to the development of promising new technologies and

Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.

About the DVD: Portfolio analysis has a long history and good track record in life sciences R&D and new product development. The methodologies for project and program evaluation and portfolio optimization based on decision and risk analysis are, by now, well established in these areas, but there is still a concern among senior managers about many of the key metrics used, due to the long time frames and high risk in life sciences R&D. Excellent portfolio management requires that decisions get made on the portfolio evaluation, so how do these portfolio decisions really get made?

This tutorial offers an introduction to the fundamentals of Proof-of-Concept (PoC) in pharmaceutical drug development. The program covers everything from the root causes of attrition to the execution of a successful PoC program in a clinical trial. Learn how and why proof-of-concept studies fail and how to manage the risks associated.